# Amplify Weight Loss Drug & Treatment ETF (THNR) — Overview

THNR · NYSE · Fund

Canonical page: https://www.lighthorse.io/tickers/thnr

## Price

Last close $24.74 on Oct 15, 2026. 52-week range $22.94 – $27.91.

## Fund profile

THNR tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses.

| Metric | Value |
| --- | --- |
| Issuer | Amplify Investments |
| Industry | Healthcare |
| Inception | May 21, 2024 |
| Assets under management | $5.6M |
| Expense ratio | 0.59% |
| Net asset value | $24.18 (as of Oct 14, 2026) |
| Distributions | Annually |
| Leverage | 1x |

## Frequently Asked Questions

### What is Amplify Weight Loss Drug & Treatment ETF (THNR)?

THNR tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses.

### What is THNR's expense ratio?

Amplify Weight Loss Drug & Treatment ETF charges an annual expense ratio of 0.59%. The fund is issued by Amplify Investments.

### How large is THNR?

Amplify Weight Loss Drug & Treatment ETF manages $5.6M in assets and has traded since May 21, 2024.

### How do I buy shares of Amplify Weight Loss Drug & Treatment ETF (THNR)?

THNR trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at [Light Horse Dashboard](https://portal.lighthorse.io), the trading API, or an [AI agent connected over MCP](/instructions/ai/claude). The trade panel on this page places the order once you are signed in.

---

Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).